Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Inventory (2017 - 2023)

Avalo Therapeutics' Change in Inventory history spans 7 years, with the latest figure at -$18000.0 for Q3 2023.

  • For Q3 2023, Change in Inventory fell 1700.0% year-over-year to -$18000.0; the TTM value through Jun 2024 reached -$18000.0, down 260.0%, while the annual FY2023 figure was -$20000.0, 11.11% down from the prior year.
  • Change in Inventory reached -$18000.0 in Q3 2023 per AVTX's latest filing, down from -$1000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $68294.0 in Q4 2019 to a low of -$411736.0 in Q2 2019.
  • Average Change in Inventory over 5 years is -$29155.1, with a median of -$3000.0 recorded in 2020.
  • Peak YoY movement for Change in Inventory: soared 600.0% in 2021, then plummeted 1700.0% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $68294.0 in 2019, then tumbled by 108.79% to -$6000.0 in 2020, then skyrocketed by 466.67% to $22000.0 in 2021, then crashed by 109.09% to -$2000.0 in 2022, then plummeted by 800.0% to -$18000.0 in 2023.
  • Per Business Quant, the three most recent readings for AVTX's Change in Inventory are -$18000.0 (Q3 2023), -$1000.0 (Q2 2023), and -$1000.0 (Q1 2023).